A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for ...

Molecular testing, including chromosomal microarray analysis, distinguishes between aggressive and indolent kidney cancer subtypes, aiding in accurate diagnosis. Accurate diagnosis is critical for ...

Camryn was diagnosed with a low-grade glioma at age two after her parents noticed a lazy eye. Sixteen years, 11 brain surgeries and over six years of chemotherapy treatment, Camryn is now ...

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study A nationwide ...

With more than 150,000 new colorectal cancer cases diagnosed annually in the United States, metastatic colorectal cancer (mCRC) remains an area of significant unmet medical need.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...

Patients with the most common molecular subtype of advanced breast cancer now have a targeted drug approved specifically for ...

Advances in medical technology have improved health in part by bringing key aspects of care, once difficult to access, into ...